Burosumab versus conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period.

Leanne M Ward, Wolfgang Högler, Francis H Glorieux, Anthony A Portale, Michael P Whyte, Craig F Munns, Ola Nilsson, Jill H Simmons, Raja Padidela, Noriyuki Namba, Hae Il Cheong, Etienne Sochett, Koji Muroya, Hiroyuki Tanaka, Pisit Pitukcheewanont, Gary S Gottesman, Andrew Biggin, Farzana Perwad, Angel Chen, J Lawrence Merritt, Erik A Imel. Burosumab versus conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period. JBMR Plus. 2024 Jan 4; ziad001.